NCT04969601View on ClinicalTrials.gov

Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

March 1, 2024

Conditions
Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Interventions
BIOLOGICAL

vaccine COMIRNATY® (BNT162b2)

two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children

Trial Locations (2)

75012

Hôpital Armand Trousseau, Paris

75019

Hôpital Robert Debré, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings | Biotech Hunter | Biotech Hunter